Evidence and Future Perspectives for Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Scoping Review

• Published in: Cancers Vol. 16; no. 9; p. 1632
• Main Authors: Endo, Yutaka, Kitago, Minoru, Kitagawa, Yuko
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 24.04.2024
• Subjects: Adjuvant treatment; Biomarkers; Cancer; Cancer therapies; Care and treatment; Chemotherapy; Clinical trials; Health aspects; Immunotherapy; Medical innovations; Medical prognosis; Medical research; Medicine, Experimental; Metastasis; Mortality; Oncology; Pancreatic cancer; Patients; Precision medicine; Review; Surgery; Survival; Tumors; pancreatic cancer; randomized controlled trials; neoadjuvant therapy; scoping review
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers16091632

Pancreatic cancer (PC) is a lethal disease that requires innovative therapeutic approaches to enhance the survival outcomes. Neoadjuvant treatment (NAT) has gained attention for resectable and borderline resectable PC, offering improved resection rates and enabling early intervention and patient sel...